Under the direction of Founder and CEO Matt Angle, Paradromics is advancing a high-data-rate brain-computer interface (BCI) designed to restore communication for people with severe motor impairments by translating neural signals directly into speech, text, and computer control.
Paradromics was founded to address a clear gap between academic promise and real-world usability in BCIs. Early systems demonstrated compelling proof of concept but lacked the performance and durability required for clinical deployment.
“We saw that while brain-computer interfaces had demonstrated incredible proof of concept in clinical research, they were limited by low data rates, poor long-term performance, and bulky through-skin connectors. They weren’t ready for deployment as robust products,” Angle explained.
With early support from DARPA, the team set out to build what Angle describes as “broadband for the brain,” focusing on high-channel-count systems capable of recording from large populations of neurons. That vision became the foundation for ConnexusⓇ BCI, now approved for a first-in-human clinical trial.
At its core, Paradromics is solving a fundamental interface problem between biology and technology.
“At the highest level, we are solving the problem that human beings don’t come with USB-C connectors, so when we need to get data in or out of the brain, we need to create a physical data interface,” Angle said.
The immediate clinical focus is restoring communication. Approximately 150,000 Americans have lost the ability to speak and have limited limb function, often due to ALS, stroke, or spinal cord injury. Many of these individuals remain cognitively intact but rely on tools such as eye-tracking systems and letter boards, which are slow and cognitively and physically demanding, limiting natural conversation.
“Communication is central to independence and everyday life. Restoring it in real time allows people to express themselves and stay connected to others,” Angle said.
Paradromics’ Connexus BCI captures neural activity at the level of individual neurons and decodes intended communication in real time. The system translates brain signals into text, synthesized speech, or cursor control, creating a direct pathway from thought to output.
At a technical level, the platform uses platinum-iridium microwire electrodes to record action potentials, preserving the timing and structure needed for high-quality decoding. This data is then processed by downstream software that interprets patterns associated with intended communication.
“Our performance and purpose define the platform,” Angle said. “The Connexus BCI records activity from individual neurons and has demonstrated data rates above 200 bits per second, more than 20 times higher than the next highest data rate BCI.”
Equally important is durability. The system is designed as a fully implantable device with no wires or components breaking the skin’s surface, and preclinical data have shown stable recordings over multiple years. This combination of high data throughput and long-term reliability is central to enabling continuous, natural communication.

Paradromics has entered the clinical stage, marking a major transition from development to real-world application.
“In 2025, we completed our first-in-human procedure, demonstrating safe implantation and stable neural signal recording,” Angle shared.
The company has also received FDA IDE approval for the Connect One clinical study, which is now enrolling patients and will evaluate safety, feasibility, and early communication performance.
Beyond this initial indication, Paradromics is building toward a broader platform roadmap. “Restoring communication is the first step in developing a massively scalable platform that’s designed to target a longstanding pipeline of neurological and psychiatric applications, benefiting millions of individuals who have been left with severely limited options for far too long,” Angle emphasized.
With its APEX Partnership Program connecting leading BCI researchers and clinicians, and a stated goal of doubling data rates with each generation, Paradromics is positioning its technology not as a single application, but as a foundational interface for future neurological and psychiatric therapies.
Angle has been selected to present at LSI Europe '26, September 28th–October 1st, in front of hundreds of global medical technology companies. Join us in welcoming him to the event in Barcelona, where he will share the latest updates on Paradromics’ technology and development.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data